ScienceDaily (July 18, 2012) A team of researchers from Mount Sinai School of Medicine and four other institutions have found that young kids with egg allergies can benefit from treatment with oral immunotherapy.
The study titled, “Oral Immunotherapy for Treatment of Egg Allergy in Children,” appears on-line in the New England Journal of Medicine on Wednesday, July 19.
In a multi-center, double-blind, randomized, placebo-controlled study of 55 kids with egg allergy, between 5 and 11 years old, 40 kids received an egg-white powder as daily oral immunotherapy and 15 kids received a cornstarch powder placebo over a 24 month period. Fifty-five kids participated in a food challenge, which is a test where a person with food allergy gradually consumes increasing amounts of the allergenic food under medical supervision in order to determine at what level the person experiences allergenic symptoms.
Children who successfully passed the food challenge at 22 months, without having an allergic reaction, discontinued oral immunotherapy and avoided all egg consumption for four to six weeks. At 24 months, these kids underwent an oral food challenge with egg-white powder and a cooked egg to test if they had developed tolerance to egg. Children who passed this challenge were placed on a diet with egg consumption and were evaluated again at 30 and 36 months.
“After 10 months of therapy, 55 percent of those who received oral immunotherapy passed the oral food challenge and were considered to be desensitized, compared to none of those on placebo,” stated Scott Sicherer, MD, Professor of Pediatrics and Chief of the Division of Allergy and Immunology at Mount Sinai School of Medicine. “After 22 months, 75 percent of kids in the oral-immunotherapy group were desensitized, meaning with their daily dose they could ingest much more egg than before.”
In the oral-immunotherapy group, 28 percent of the kids passed the oral food challenge at 24 months after being off daily therapy for 4 to 6 weeks and were considered to no longer have an allergy to egg. At 30 months and 36 months, all kids who had passed the oral food challenge at 24 months were consuming egg.
“We found that oral immunotherapy provides protection in a majority of kids with egg allergy by raising the reaction threshold,” stated Hugh Sampson, MD, Dean for Translational Biomedical Sciences, Professor of Pediatrics, and Director of the Jaffe Food Allergy Institute at Mount Sinai School of Medicine. “It represents a promising therapeutic intervention for food allergy and the approach is relatively safe, with most of the reactions to dosing categorized as mild.”
Approximately 15 percent of the kids who received oral immunotherapy did not complete the therapy due to significant clinical reactions. The mechanisms underlying the success of oral immunotherapy and their relationship to natural immune tolerance are unknown.
“For oral immunotherapy to be recommended as a standard of care, it will be important to better define the risks of oral immunotherapy versus avoiding the food the child is allergic to, and determine the correct dosing regimens with the most favorable outcomes,” stated Dr. Sampson. “It is also important to identify patients who are most likely to benefit from oral immunotherapy, and develop strategies that promote long-term tolerance.”
The trial was conducted by the National Institute of Allergy and Infectious Diseases (NIAID)-supported Consortium of Food Allergy Research (CoFAR) at clinical sites in Baltimore; Chapel Hill, N.C.; Denver; Little Rock, Ark.; and New York City.
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
The above story is reprinted from materials provided by The Mount Sinai Hospital / Mount Sinai School of Medicine, via EurekAlert!, a service of AAAS.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
- Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia
- Impact of Medicaid expansion would vary by state, according to study
- Fish, But Not Fish Oil Supplements, May Shield Against Stroke
- Antidepressant eases radiation-related mouth pain in head, neck cancer
- Study: More Birth Defects with In Vitro
- Antidepressants and Stroke
- Vaccine Safety
- Children and CT Concerns
- Study: Hint of Benefit for Alzheimer’s Drug
- Study provides direct evidence for persistent activity in medial entorhinal cortex layer neurons
Submited at Thursday, July 19th, 2012 at 8:30 am on Uncategorized by sofia
Comment RSS 2.0 - leave a comment - trackback